News

The research neuropsychologist at Mount Sinai Rehabilitation Hospital outlined hallmark patterns of cognitive impairment in multiple sclerosis at the 2026 CMSC Annual Meeting. [WATCH TIME: 6 minutes]

From patient questions to clinical trial referrals, this episode highlights practical strategies for counseling individuals interested in stem cell-based therapies for Parkinson disease.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

A clinical research coordinator at SunnyBrook Health Sciences Centre, explained key factors of the computerized cognitive training program that contributed to cognitive improvement. [WATCH TIME: 3 minutes]

The neurologist at St. Michael's Hospital shared findings presented at CMSC 2026 from a large dataset on preconception ocrelizumab exposure among women with multiple sclerosis. [WATCH TIME: 5 minutes]

Neurologists Roger Barker, MBBS, MRCP, PhD, FMedSci, and Claire Henchcliffe, MD, DPhil, discuss the development, goals, and educational value of ISSCR's new stem cell medicine course for Parkinson disease.

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.

Updated clinical data highlight opakalim’s ongoing development in epilepsy, with pivotal focal epilepsy results expected later this year.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mmoldering inflammation in MS!

At CMSC 2026, Jamie Lynn Sigler, an actress and patient advocate, shared her perspective on living with multiple sclerosis, emphasizing informed decision-making and treatment consistency. [WATCH TIME: 7 minutes]

Christina Xia, MD, a stroke specialist at Cleveland Clinic, reviewed recent advances in stroke rehabilitation, including neuromodulation and emerging approaches aimed at improving long-term recovery after stroke.

Neurology News Network for the week ending May 30, 2026. [WATCH TIME: 4 minutes]

The director of the Stony Broke MS Comprehensive Care Center reviewed late-breaking subgroup data evaluating high-efficacy therapy in patients with highly active relapsing multiple sclerosis and discussed the evolving role of early intervention. [WATCH TIME: 5 minutes]

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Todd Arnedt, PhD. [LISTEN TIME: 18 minutes]

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

A retrospective study presented at CMSC 2026 found GLP-1 receptor agonist use in multiple sclerosis was associated with higher physical activity levels and improvements across several patient-reported symptom domains.

Three-year extension data presented at CMSC 2026 showed sustained suppression of MRI activity and low relapse rates with frexalimab in relapsing multiple sclerosis.

A new analysis presented at CMSC 2026 suggests that rescue treatment with complement inhibition may help stabilize disease activity in Hispanic patients with NMOSD who experienced relapse despite treatment.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Joohi Jimenez-Shahed, MD, professor of neurology at Mount Sinai, commented on the evolving understanding of Tourette syndrome, persistent misconceptions, and emerging therapeutic and neuromodulation approaches for tic disorders.

New exon‑51 skipping therapy boosts dystrophin and patient strength, with upcoming trial readouts aiming to support accelerated FDA approval.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.